Despite a positive outcome for some patients with an aggressive form of breast cancer, metastatic triple-negative breast cancer (TNBC), treated with Roche's PD-L1 inhibitor Tecentriq, the study shows that questions about why some patients respond to treatment while others do not continue to challenge the immuno-oncology field.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?